Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab A/S raises FY 2013 financial guidance


Tuesday, 26 Nov 2013 01:47am EST 

Genmab A/S:Says FY 2013 guidance has improved due to the achievement of $8 million daratumumab milestone.Says FY 2013 revenue is now expected to be of 595 - 635 million Danish krone and FY 2013 operating result from continuing operations to be of between negative 30 million Danish krone and positive 35 million Danish krone.Says previous guidance was revenue of 550 - 590 million Danish krone and operating loss of 10 - 75 million Danish krone in FY 2013.FY 2013 revenue 597.35 million Danish krone, FY 2013 EBIT 6.98 million Danish krone-Thomson Reuters I/B/E/S. 

Company Quote

237.8
4.0 +1.71%
19 Sep 2014